ASX Share rice
Thu 13 May 2021 - 12:37:pm (Sydney)

ATX Share Price

AMPLIA THERAPEUTICS LIMITEDATXPharmaceuticals, Biotechnology & Life Sciences

ATX Company Information


Amplia Therapeutics Limited





GIC Industry:


GIC Sub Industry:



90 Collins Street Melbourne VIC Australia 3000


61 2 8003 3650

CEO, MD & Director:

Dr. John Lambert B.Sc., BSc (Hons), MRACI, C.Chem., Ph.D.

Chief Financial Officer:

Mr. Jeff Carter

Company Sec.:

Mr. Andrew John Cooke LLB, FAICS, MAICD, FGIA, FCIS

Chief Scientific Officer:

Dr. Mark Devlin B.Sc., Ph.D.

Founding Scientist:

Dr. Frank Gelder

Trials Consultant:

Dr. James A. Taylor

Trials Consultant:

Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR

Clinical Consultant:

Dr. Benjamin M. Segal

Toxicology Consultant:

Dr. Frederick E. Reno

Company Overview:

Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

ATX Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


ATX CashFlow Statement

CashFlow Date:


Change To Liabilities:


Net Income:


Total Cash From Operating Activities:




Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


ATX Income Statement

Income Date:


Income Before Tax:


Net Income:


Operating Income:


Total Revenue:


ATX Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


ATX Share Price History

ATX News

24 Feb, 2021
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
26 Nov, 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
30 May, 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...